Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. 2019

Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany; Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany; Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany. Electronic address: guido.moll@charite.de.

Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue
D045164 Mesenchymal Stem Cell Transplantation Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Stem Cell Transplantation, Mesenchymal,Transplantation, Mesenchymal Stem Cell
D059630 Mesenchymal Stem Cells Mesenchymal stem cells, also referred to as multipotent stromal cells or mesenchymal stromal cells are multipotent, non-hematopoietic adult stem cells that are present in multiple tissues, including BONE MARROW; ADIPOSE TISSUE; and WHARTON JELLY. Mesenchymal stem cells can differentiate into mesodermal lineages, such as adipocytic, osteocytic and chondrocytic. Adipose Tissue-Derived Mesenchymal Stem Cell,Adipose Tissue-Derived Mesenchymal Stromal Cell,Adipose-Derived Mesenchymal Stem Cell,Bone Marrow Mesenchymal Stem Cell,Mesenchymal Stromal Cell,Mesenchymal Stromal Cells,Multipotent Bone Marrow Stromal Cell,Multipotent Mesenchymal Stromal Cell,Adipose Tissue-Derived Mesenchymal Stem Cells,Adipose Tissue-Derived Mesenchymal Stromal Cells,Adipose-Derived Mesenchymal Stem Cells,Adipose-Derived Mesenchymal Stromal Cells,Bone Marrow Mesenchymal Stem Cells,Bone Marrow Stromal Cell,Bone Marrow Stromal Cells,Bone Marrow Stromal Cells, Multipotent,Bone Marrow Stromal Stem Cells,Mesenchymal Progenitor Cell,Mesenchymal Progenitor Cells,Mesenchymal Stem Cell,Mesenchymal Stem Cells, Adipose-Derived,Mesenchymal Stromal Cells, Multipotent,Multipotent Bone Marrow Stromal Cells,Multipotent Mesenchymal Stromal Cells,Stem Cells, Mesenchymal,Wharton Jelly Cells,Wharton's Jelly Cells,Adipose Derived Mesenchymal Stem Cell,Adipose Derived Mesenchymal Stem Cells,Adipose Derived Mesenchymal Stromal Cells,Adipose Tissue Derived Mesenchymal Stem Cell,Adipose Tissue Derived Mesenchymal Stem Cells,Adipose Tissue Derived Mesenchymal Stromal Cell,Adipose Tissue Derived Mesenchymal Stromal Cells,Mesenchymal Stem Cells, Adipose Derived,Progenitor Cell, Mesenchymal,Progenitor Cells, Mesenchymal,Stem Cell, Mesenchymal,Stromal Cell, Mesenchymal,Stromal Cells, Mesenchymal,Wharton's Jelly Cell,Whartons Jelly Cells

Related Publications

Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
January 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
January 2008, Scandinavian journal of clinical and laboratory investigation,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
January 2017, Cytotherapy,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
October 2023, Stem cells (Dayton, Ohio),
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
November 2020, Diagnostics (Basel, Switzerland),
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
April 2021, Journal of biomedical science,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
January 2016, F1000Research,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
January 2020, Journal of clinical medicine,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
October 2019, Cytotherapy,
Guido Moll, and James A Ankrum, and Julian Kamhieh-Milz, and Karen Bieback, and Olle Ringdén, and Hans-Dieter Volk, and Sven Geissler, and Petra Reinke
June 2013, Acta pharmacologica Sinica,
Copied contents to your clipboard!